Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

FDA grants marketing clearance to Crospon's EndoFLIP product

Crospon, an Irish medical device developer based in Galway, has announced that the Company has received clearance from the US Food and Drugs Administration to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.

6 Jan 2011

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

A tiny light source and sensors at the end of an endoscope may provide a more accurate way to identify pre-cancerous cells in the lining of the esophagus.

4 Jan 2011

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

A select 40 physician-researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center were named 2011 Southern California Super Doctors in the January issue of Los Angeles Magazine.

4 Jan 2011

Children more likely to suffer from appendicitis in areas with few pediatricians

Children who live in areas with fewer pediatricians are more likely to suffer life-threatening ruptures of the appendix than those in areas with more pediatricians, even when accounting for other factors such as the number of hospitals, imaging technology, insurance coverage and the number of surgeons in an area, according to a study from the Johns Hopkins Children's Center.

30 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases.

29 Dec 2010

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Placebos work

According to a new study people who knowingly take a dummy pill or placebo may benefit from it. These pills are usually made from sugar or other inert non-harmful materials. Usually when used in clinical trials patients are unaware whether they are taking the tested drug or a placebo to ensure the medical benefits of a potential new drug are assessed rigorously. However this new study published in the science journal PLoS ONE, found placebos may work even when patients are aware that they are taking them.

27 Dec 2010

Good Clostridia prevents development of allergies and inflammatory bowel disease

Scientists at the University of Tokyo have discovered that specific gut-dwelling bacteria control key immune cells that combat allergies and autoimmune diseases. The paper describing these findings was published in today's issue of the journal Science, and technology originating from the work is being advanced by start-up Vedanta Biosciences.

24 Dec 2010

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

23 Dec 2010

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.

23 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Acetadote® (acetylcysteine) Injection to treat patients with non-acetaminophen induced acute liver failure.

22 Dec 2010

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Intellipharmaceutics International, today announced that it has notified the U.S. Food and Drug Administration that it has not received notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer, for its application to market a generic of Wyeth's Protonix® tablets.

22 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

Contamination with potential disease-causing bacteria is commonly found on hands of anesthesia providers

Contaminating bacteria are very commonly found on the hands of anesthesia providers, with high rates of transmission to the surgical field during operations, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

22 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

FDA grants marketing clearance to Crospon's EndoFLIP product

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

Los Angeles Magazine declares LA BioMed physicians as 2011 Southern California Super Doctors

Children more likely to suffer from appendicitis in areas with few pediatricians

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

CFTR protein regulates inflammation and cell death in emphysema, chronic lung diseases

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Placebos work

Good Clostridia prevents development of allergies and inflammatory bowel disease

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Contamination with potential disease-causing bacteria is commonly found on hands of anesthesia providers

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in